From a biological perspective, there is no a priori reason why newly diagnosed grade 3 tumors cannot be responsive to IDH inhibitors and other clinical, radiological, and molecular factors need consideration (like growth rate, histology, other molecular findings, and pre-and postoperative tumor volume). This evidence concerns the gene IDH2 and neoplasm.